Despite the extensive body of literature on rheumatoid arthritis (RA), the exact causes of the disease are not fully understood. Tumor necrosis factor alpha (TNF) is known to play a key role in the disease by stimulating catabolic processes and causing inflammation, and important elements of inflammation include changes in extracellular matrix compounds and their constituents, such as glycosaminoglycans.
Despite the extensive body of literature on rheumatoid arthritis (RA), the exact causes of the disease are not fully understood. Tumor necrosis factor alpha (TNF) is known to play a key role in the disease by stimulating catabolic processes and causing inflammation, and important elements of inflammation include changes in extracellular matrix compounds and their constituents, such as glycosaminoglycans (GAGs). GAGs are thought to play a role in RA pathogenesis; a recent study sought to describe the impact of anti-TNF agents on GAG levels in women patients with RA.
A total of 45 female patients who had an inadequate response to at least 2 disease-modifying anti-rheumatic drugs were recruited for the study; 22 received adalimumab, 19 received etanercept, and 4 received certolizumab pegol. All patients continued to take methotrexate and prednisone. Twenty age-matched volunteers were included as controls.
Sixteen patients were excluded from the study due to lack of efficacy, loss of response, withdrawal of consent, intolerance, or surgical procedures. The remaining 29 patients, all of whom responded well to biologic treatment, completed 15 months of therapy. A total of 38% achieved remission at month 9, and 80% achieved remission at month 15. The remaining patients had low disease activity.
In these patients, at 3 months, a statistically significant decrease in total GAG level was observed, and GAG levels continued to drop with therapy until levels matched those of the controls.
“To the best of our knowledge, this is the first study that reports an association between good clinical response to anti-TNF treatments and the plasma GAGs in RA patients,” write the authors, adding that the reduced GAG levels may be due to reduced enzymatic a nonenzymatic catabolic processes as a result of therapy.
The authors concluded that anti-TNF therapy in women patients with RA has a beneficial effect on metabolism of tissue GAGs, and that normalization of plasma levels of GAGs suggests improvement in the extracellular matrix remodeling balance.
Reference
Szeremeta A, Jura-Półtorak A, Koźma EM. Effects of a 15-month anti-TNF-a treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis. Arthritis Res Ther. 2018;20: 211. doi: 10.1186/s13075-018-1711-z.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.